Deep mutational learning for the selection of therapeutic antibodies resistant to the evolution of Omicron variants of SARS-CoV-2.

Most antibodies for treating COVID-19 rely on binding the receptor-binding domain (RBD) of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). However, Omicron and its sub-lineages, as well as other heavily mutated variants, have rendered many neutralizing antibodies ineffective. Here we show that antibodies with enhanced resistance to the evolution of SARS-CoV-2 can be identified via deep mutational learning.

Secondary Resections and Survival After Breast-Conserving Surgery in Breast Cancer Patients: A Cancer Registry-Based Cohort Study.

Breast cancer remains the most common malignancy in women, and breast-conserving surgery (BCS) with adjuvant radiotherapy is a standard treatment for early-stage disease. This study assessed the impact of positive surgical margins and secondary surgeries on local recurrence rates and patient outcomes. In this retrospective tumor registry-based study, 24,450 women were eligible for analysis.

Clinical characteristics, metastasis patterns, and treatment outcomes of HER2-low breast cancer.

Breast cancer (BC) is a heterogeneous disease, traditionally classified by hormone receptor and HER2 (human epidermal growth factor receptor 2) status. HER2-low, characterized by low HER2 expression without gene amplification, recently gained attention. While new therapies are promising, its clinical significance remains unclear.

Graphical modeling of additive color mixing. Perception of objects with different color shades for different observers.

Objective: Aim: To research subjective perceptions in additive color mixing.

Patients And Methods: Materials and Methods: 79 individuals were surveyed, and they determined the colors they perceived in two photographs. The results of color mixing were determined using statistical analysis, graphical modeling, and Python program figures.

Prognostic Impact of HER2 Low Status in Male Breast Cancer: Prospective Cohort Analysis.

Background: Male breast cancer (MBC) is a rare disease, and the potential influence of low expression of human epidermal growth factor receptor 2 (HER2 low) remains unexplored.

Methods: In this prospective cohort study, we evaluated 870 patients treated for MBC between May 2009 and June 2023 to assess HER2 low status and its prognostic implications.

Results: With a median follow-up of 43 months (range 1-175 months), 659 eligible patients were categorized into three groups based on HER2 status: 501 (76%) HER2 low, 81 (12.